S997
Clinical - Oligometastatic cancer
ESTRO 2026
Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023;9(6):825-834. doi:10.1001/jamaoncol.2023.0161Huynh LM, Bonebrake BT, Enke C, Baine MJ. Survival Outcomes After Radiotherapy for the Treatment of Synchronous Oligometastatic Prostate Cancer. JAMA Netw Open. 2022;5(10):e2235345. doi:10.1001/jamanetworkopen.2022.35345 Keywords: node-positive HSPC, whole pelvic radiotherapy
Conclusion: Comparable OS, bRFS, and DMFS between N1M0 and M1a disease suggest that non-regional node–only metastases may represent a locoregional phenotype when treated with WPRT and ENI. Prospective validation is warranted to optimize elective field design and confirm these findings. References: Tang C, Sherry AD, Haymaker C, et al. Addition of Metastasis-Directed Therapy to Intermittent Hormone
Made with FlippingBook - Share PDF online